Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
NAV 26 is a selective Nav1.7 channel blocker (IC50 = 370 nM). Exhibits >85-fold selectivity for Nav1.7 over Nav1.5 and hERG channels. Reduces nociceptive behavior in rat models of pain.
NAV 26 is also offered as part of the Tocriscreen 2.0 Max. Find out more about compound libraries available from Tocris.
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
The following data is based on the product molecular weight 434.41. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.3 mL||11.51 mL||23.02 mL|
|5 mM||0.46 mL||2.3 mL||4.6 mL|
|10 mM||0.23 mL||1.15 mL||2.3 mL|
|50 mM||0.05 mL||0.23 mL||0.46 mL|
References are publications that support the biological activity of the product.
Macsari et al (2012) 3-Oxoisoindoline-1-carboxamides: potent, state-dependent blockers of voltage-gated sodium channel Na(V)1.7 with efficacy in rat pain models. J.Med.Chem. 55 6866 PMID: 22770500
If you know of a relevant reference for NAV 26, please let us know.
Keywords: NAV 26, NAV 26 supplier, NAV26, selective, NAv1.7, ion, channels, blockers, Voltage-gated, Sodium, Channels, 4691, Tocris Bioscience
Citations are publications that use Tocris products.
Currently there are no citations for NAV 26. Do you know of a great paper that uses NAV 26 from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review NAV 26 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.